HALObenzinga

Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $62

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 14, 2025 by benzinga